|

Nimotuzumab Clinical Trials

18 actively recruiting trials

No change since May 2026

Also known as: BIOMAb EGFR, Nim, Nimotuzumab Injection, Nimotuzumab injection, Taixinsheng +2 more

Pipeline

Phase 2: 12Phase 3: 5

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital3
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences3
  • Zhejiang University1
  • Zhejiang Provincial People's Hospital1
  • The First Affiliated Hospital with Nanjing Medical University1

Indications

  • Cancer18
  • Head Neck Cancer3
  • Head & Neck Squamous Cell Carcinoma2
  • Nasopharyngeal Carcinoma by AJCC V8 Stage2
  • Chemoradiation2

Other18 trials

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Phase 3
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Phase 3
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
N/A
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Phase 2
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Phase 2
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Phase 2
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
Phase 3
Neoadjuvant Treatment Modalities in Esophageal Cancer
Phase 3
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
Phase 2
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
Phase 2
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Phase 2
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Phase 2
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Phase 2
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
Phase 3
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
Phase 2
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.